Primary extranodal non-hodgkin's lymphoma of the head and neck
Date
1992Author
Economopoulos, T.Asprou, N.
Stathakis, N.
Fountzilas, George

Papaspyrou, S.

Belia, M.
Papageorgiou, E.
Theoharis, D.
Vrettou, E.
Raptis, S.
Source
Oncology (Switzerland)Volume
49Issue
6Pages
484-488Google Scholar check
Keyword(s):
Metadata
Show full item recordAbstract
Among 387 cases of non-Hodgkin's lymphoma (NHL) treated in our units between January 1977 and December 1990, 52 (13.4%) had primary extranodal (PE) NHL of the head and neck. The median age was 55 years with a M:F ratio of 1.9: 1. The most frequent primary site was the tonsil (28 cases), followed by oral cavity, parotid gland, orbit and other sites. The aggressive histological subtypes predominate. 55.2% of the patients were in stage I and 44.8% in stage II of disease. The CR rate was high (94.2%). The 5 years' overall survival rate was 65% and it was influenced mainly by stage (stage I 82.5% vs. 48.7% in stage II). Sex, age and histology did not significantly affect survival rate. Patients with primary Waldeyer's ring involvement (WR group) did not differ significantly from the other primary sites analyzed as a group (non-WR group) in respect to median age, sex distribution, histology and CR rates. They differed, however, in: (1) stage distribution with stage II disease more frequent in the WR group; (2) overall survival and disease-free survival both of which were significantly better in the non-WR group; and (3) the high incidence of GI tract involvement as initial manifestation of relapse in the WR group. It is concluded that the behaviour of the Waldeyer's ring PE-NHL is rather distinctive and should be considered separately from the other PE-NHL of the head and neck. © 1992 S. Karger AG, Basel.
Collections
Cite as
Related items
Showing items related by title, author, creator and subject.
-
Article
Non-Hodgkin's Lymphomas in Greece according to the WHO classification of lymphoid neoplasms a retrospective analysis of 810 cases
Economopoulos, T.; Papageorgiou, S.; Dimopoulos, M. A.; Pavlidis, Nicholas; Tsatalas, C.; Symeonidis, A.; Foudoulakis, A.; Pectasides, Dimitrios; Rontogianni, D.; Rizos, E.; Chalkia, P.; Anagnostopoulos, A.; Melachrinou, M.; Papageorgiou, E.; Fountzilas, George (2005)The purpose of this retrospective study, the largest unselected series in our country, was to illustrate the clinicopathological features of non-Hodgkin's lymphoma (NHL) classified according to the World Health Organization ...
-
Article
Multifocal extranodal non-Hodgkin lymphoma: A clinicopathologic study of 37 cases in Greece, a Hellenic Cooperative Oncology Group Study
Economopoulos, T.; Papageorgiou, S.; Rontogianni, D.; Kaloutsi, V.; Fountzilas, George; Tsatalas, C.; Pavlidis, Nicholas; Pectasides, Dimitrios; Papageorgiou, E.; Dimopoulos, M. A. (2005)The purpose of this retrospective study was to illustrate the clinicopathological features of patients presenting with multifocal extranodal non-Hodgkin lymphoma (NHL). Among 810 patients with NHL, 37 cases (4.2%) were ...
-
Article
CEOP-21 versus CEOP-14 chemotherapy with or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the hellenic cooperative oncology group
Economopoulos, T.; Psyrri, A.; Dimopoulos, M. A.; Kalogera-Fountzila, Anna; Pavlidis, Nicholas; Tsatalas, C.; Nikolaides, C.; Mellou, S.; Xiros, N.; Fountzilas, George (2007)Background: In this study we investigated whether administering CEOP (cyclophosphamide, epirubicin, vincristine [Oncovin], and prednisone) every 2 weeks (CEOP-14) instead of every 3 weeks (the standard CEOP-21 regimen) ...